Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | See Remarks | August 20, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neumora Therapeutics, Inc.
Report date August 20, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2036-08-20 | Direct | 375,000 |
Reported balance
After 2026-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-20 · Grant · Acquired 375,000 · Balance 375,000 F1: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALBIREO PHARMA, INC.
Report date March 02, 2023 · Filed March 02, 2023
Section 16 reporting ended · disclosed 2023-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 1
1 source rowRow 1 · 2023-03-02 · Other · Disposed 3,296 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the "Closing Amount") F2: (Continued from Footnote 1) plus one non-tradeable contractual contingent value right ("CVR" and each CVR together with the Closing Amount, the "Offer Price"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the "CVR Agreement") on or prior to December 31, 2027 (the "Milestone"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.75 · Expires 2032-01-17 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-02 · Disposition to issuer · Disposed 15,900 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.04 · Expires 2029-01-21 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-02 · Disposition to issuer · Disposed 10,063 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.67 · Expires 2030-01-20 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-02 · Disposition to issuer · Disposed 24,337 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.88 · Expires 2031-01-20 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-02 · Disposition to issuer · Disposed 23,700 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.68 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-02 · Disposition to issuer · Disposed 37,500 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-03-02 · Disposition to issuer · Disposed 65,850 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one Share. F6: Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F7: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the "Closing Amount")
F2: (Continued from Footnote 1) plus one non-tradeable contractual contingent value right ("CVR" and each CVR together with the Closing Amount, the "Offer Price"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the "CVR Agreement") on or prior to December 31, 2027 (the "Milestone").
F3: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option")
F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect.
F5: Each restricted stock unit represents a contingent right to receive one Share.
F6: Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect.
F7: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2021 Filed Apr 26, 2021 18:13 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 90 | $31.75 | $2,857.50 |
DisclosureSEC source: 0001209191-21-028384 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,071 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 383 shares of common stock and 7,688 restricted stock units. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:55 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Exercise / conversionStock Option (right to buy) · Derivative | 300 | $0.00 Strike: $24.04 | $0.00 |
DisclosureSEC source: 0001209191-21-024891 · doc4.xml · derivative · entry 4 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 Underlying: Common Stock · 300 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option vested as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:55 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 300 | $36.16 | $10,847.01 |
DisclosureSEC source: 0001209191-21-024891 · doc4.xml · nonDerivative · entry 3 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,161 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. Includes 72 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2019; 87 shares of common stock acquired under the ESPP on November 30, 2019; and 96 shares of common stock acquired under the ESPP on May 31, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.09 to $36.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Represents 161 shares of common stock and 8,000 restricted stock units. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:55 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Exercise / conversionCommon Stock | 300 | $24.04 | $7,212.00 |
DisclosureSEC source: 0001209191-21-024891 · doc4.xml · nonDerivative · entry 2 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Represents 461 shares of common stock and 8,000 restricted stock units. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 20:55 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 1,426 | $35.04 | $49,969.46 |
DisclosureSEC source: 0001209191-21-024891 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,161 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. Includes 72 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2019; 87 shares of common stock acquired under the ESPP on November 30, 2019; and 96 shares of common stock acquired under the ESPP on May 31, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.54 to $35.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Represents 161 shares of common stock and 8,000 restricted stock units. Read SEC document |
| January 22, 2021 Filed Jan 25, 2021 17:44 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 110 | $34.62 | $3,808.20 |
DisclosureSEC source: 0001209191-21-005162 · doc4.xml · nonDerivative · entry 2 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,332 F3 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F4 · balance_after: Represents 1,332 shares of common stock and 8,000 restricted stock units. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 17:44 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantStock Option (right to buy) · Derivative | 23,700 | $0.00 Strike: $34.88 | $0.00 |
DisclosureSEC source: 0001209191-21-005162 · doc4.xml · derivative · entry 3 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 Underlying: Common Stock · 23,700 shares Expires 2031-01-20 F5 · derivative.exercise_date: This option vests as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 17:44 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantCommon Stock | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-005162 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,442 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025. F2 · balance_after: Represents 1,129 shares of common stock and 8,313 restricted stock units. Includes 161 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| October 22, 2020 Filed Oct 23, 2020 16:19 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 89 | $34.71 | $3,089.19 |
DisclosureSEC source: 0001209191-20-055674 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,781 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 968 shares of common stock and 2,813 restricted stock units. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:54 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Exercise / conversionStock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $24.04 | $0.00 |
DisclosureSEC source: 0001209191-20-050081 · doc4.xml · derivative · entry 3 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 3,500 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vested as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:54 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 4,000 | $45.55 | $182,200.00 |
DisclosureSEC source: 0001209191-20-050081 · doc4.xml · nonDerivative · entry 2 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,870 F2 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2019. F3 · balance_after: Represents 745 shares of common stock and 3,125 restricted stock units. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:54 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Exercise / conversionCommon Stock | 3,500 | $24.04 | $84,140.00 |
DisclosureSEC source: 0001209191-20-050081 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Represents 4,745 shares of common stock and 3,125 restricted stock units. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 16:23 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 91 | $25.80 | $2,347.80 |
DisclosureSEC source: 0001209191-20-043475 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,370 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 1,245 shares of common stock and 3,125 restricted stock units. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:20 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 92 | $17.68 | $1,626.56 |
DisclosureSEC source: 0001209191-20-025642 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,461 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 1,023 shares of common stock and 3,438 restricted stock units. Read SEC document |
| January 22, 2020 Filed Jan 23, 2020 19:22 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 447 | $23.97 | $10,714.59 |
DisclosureSEC source: 0001209191-20-004740 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,553 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.95 to $24.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Represents 803 shares of common stock and 3,750 restricted stock units. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 19:22 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantStock Option (right to buy) · Derivative | 31,500 | $0.00 Strike: $24.67 | $0.00 |
DisclosureSEC source: 0001209191-20-004740 · doc4.xml · derivative · entry 2 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2030-01-20 F4 · derivative.exercise_date: This option vests as to 25% of the shares on January 21, 2021, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2021 and ending on January 21, 2024, provided that the vesting of the option may be accelerated, in whole or in part, based on the achievement of certain pre-established company performance criteria, but in no event prior to January 21, 2021. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 18:45 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $24.04 | $0.00 |
DisclosureSEC source: 0001209191-19-005239 · doc4.xml · derivative · entry 2 Duncan Jason · CIK 0001741553 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2029-01-21 F2 · derivative.exercise_date: This option vests as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 18:45 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-005239 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023. F1 · balance_after: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 16:12 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $30.68 | $0.00 |
DisclosureSEC source: 0001209191-18-036914 · doc4.xml · derivative · entry 1 Duncan Jason · CIK 0001741553 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2028-06-07 F1 · derivative.exercise_date: This option vests as to 25% of the shares on June 8, 2019 with the remainder vesting in equal installments on the last day of 12 consecutive calendar quarters beginning on June 30, 2019 and ending on March 31, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.